- Home
- Publications
- Publication Search
- Publication Details
Title
Nanobody-based CAR-T cells for cancer immunotherapy
Authors
Keywords
-
Journal
Biomarker Research
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-25
DOI
10.1186/s40364-022-00371-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA approves second BCMA-targeted CAR-T cell therapy
- (2022) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Immunogenicity Risk Profile of Nanobodies
- (2021) Chloé Ackaert et al. Frontiers in Immunology
- In like a lamb; out like a lion: Marching CAR-T cells towards enhanced efficacy in ALL
- (2021) Pouya Safarzadeh Kozani et al. MOLECULAR CANCER THERAPEUTICS
- CAR T-cell therapy in multiple myeloma: more room for improvement
- (2021) Phaik Ju Teoh et al. Blood Cancer Journal
- Strategies for Dodging the Obstacles in CAR T Cell Therapy
- (2021) Pooria Safarzadeh Kozani et al. Frontiers in Oncology
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.
- (2021) Lu Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
- (2021) Aibin Liang et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
- (2021) Nicholas A. Vitanza et al. NATURE MEDICINE
- A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
- (2021) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Novel antigens of CAR T cell therapy: New roads; old destination
- (2021) Pooria Safarzadeh Kozani et al. Translational Oncology
- VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
- (2021) Evripidis Lanitis et al. Journal for ImmunoTherapy of Cancer
- A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma
- (2021) Mingzhi Zhang et al. BLOOD
- Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic
- (2021) Pooria Safarzadeh Kozani et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
- (2021) Pouya Safarzadeh Kozani et al. Stem Cell Research & Therapy
- Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
- (2021) Pouya Safarzadeh Kozani et al. Frontiers in Immunology
- Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
- (2020) Stijn De Munter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
- (2020) Dongrui Wang et al. Science Translational Medicine
- Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments
- (2020) Yushu Joy Xie et al. Cancer Immunology Research
- Engineering CAR-T Cells for Next-Generation Cancer Therapy
- (2020) Mihe Hong et al. CANCER CELL
- CAR-T design: Elements and their synergistic function
- (2020) Jayapriya Jayaraman et al. EBioMedicine
- The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
- (2020) Panyuan Li et al. Frontiers in Oncology
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
- (2020) Mohadese Hashem Boroojerdi et al. MEDICAL ONCOLOGY
- PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model
- (2020) Jamal Alzubi et al. Molecular Therapy-Oncolytics
- Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
- (2020) Lu Han et al. Journal for ImmunoTherapy of Cancer
- Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer
- (2019) Mahmoud Hassani et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy
- (2019) Fatemeh Hajari Taheri et al. IUBMB LIFE
- Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
- (2019) Boris Gorovits et al. BIODRUGS
- The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
- (2019) Lu Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
- (2019) Yushu Joy Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
- (2019) Mazyar Shadman et al. BLOOD
- Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia
- (2019) Cheng Qian et al. CLINICAL CANCER RESEARCH
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Jiang Cao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nanobody Based Dual Specific CARs
- (2018) Stijn De Munter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
- (2018) Ying Wang et al. Journal of Hematology & Oncology
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Targeting G protein-coupled receptor signaling at the G protein level with a selective nanobody inhibitor
- (2018) Sahil Gulati et al. Nature Communications
- From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
- (2018) Susann Albert et al. Oncotarget
- Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
- (2018) Na An et al. MOLECULAR PHARMACEUTICS
- In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas
- (2018) Carlos A. Ramos et al. MOLECULAR THERAPY
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
- (2018) Najat Bouchkouj et al. CLINICAL CANCER RESEARCH
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma
- (2018) Yi-Han Dong et al. OncoTargets and Therapy
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential
- (2017) Yuan Yu et al. International Journal of Nanomedicine
- Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
- (2017) Vinay Prasad Nature Reviews Clinical Oncology
- Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
- (2017) Nan Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Localized CD47 blockade enhances immunotherapy for murine melanoma
- (2017) Jessica R. Ingram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FDA Approves Second CAR T-cell Therapy
- (2017) Cancer Discovery
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
- (2017) Susann Albert et al. OncoImmunology
- VEGFR2 Expression in Head and Neck Squamous Cell Carcinoma Cancer Cells Mediates Proliferation and Invasion
- (2016) Hui-Min Xu et al. Asian Pacific Journal of Cancer Prevention
- Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
- (2016) Oladapo O. Yeku et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
- (2015) M. J. Frigault et al. Cancer Immunology Research
- The Emergence of T-Bodies/CAR T Cells
- (2014) Zelig Eshhar et al. CANCER JOURNAL
- The role of CD33 as therapeutic target in acute myeloid leukemia
- (2014) Roland B Walter EXPERT OPINION ON THERAPEUTIC TARGETS
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy
- (2013) Fatemeh Rahimi Jamnani et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents
- (2012) Zahra Sharifzadeh et al. CANCER LETTERS
- A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells
- (2012) Sepideh Khaleghi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation
- (2012) E. E. Weatherill et al. PROTEIN ENGINEERING DESIGN & SELECTION
- A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies
- (2012) Wei Sun et al. PROTEIN EXPRESSION AND PURIFICATION
- Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase
- (2011) Farnoush Jafari Iri-Sofla et al. EXPERIMENTAL CELL RESEARCH
- 4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection
- (2011) V. Vezys et al. JOURNAL OF IMMUNOLOGY
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Large double copy vectors are functional but show a size-dependent decline in transduction efficiency
- (2010) Tomas J. Bos et al. JOURNAL OF BIOTECHNOLOGY
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
- (2009) Seyed Hamid Aghaee Bakhtiari et al. HYBRIDOMA
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy
- (2008) N. A. Dallas et al. CLINICAL CANCER RESEARCH
- General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
- (2008) Cécile Vincke et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More